Latest From MolMed SPA
Single treatment for one eye costs £80,000 but Chiesi is offering a discount for Europe's first approved stem cell medicinal product.
US FDA and European Medicines Agency may expand sharing beyond manufacturing inspections to clinical trials and generic drug applications.
Two orphan medicines have been withdrawn from the evaluation process at the European Medicines Agency, one of them for recurrent nephrotic syndrome, the other for mesothelioma. Three products are undergoing a re-evaluation after an initial negative opinion from the CHMP.
Two biopharma IPOs in the US continue streak of (mostly) positive returns; two new European VC funds launch as Irish antibiotic developer raises $65m; and Halozyme, Ziopharm price offerings.
- Gene Therapy, Cell Therapy
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- MolMed SPA
- Senior Management
Claudio Bordignon, MD, Pres. & CEO
Enrico Cappelli, CFO
Gian Paolo, MD, Dir., Research
Holger Neecke, PhD, Mgr., Bus. Dev.
- Contact Info
Phone: (39) 2 21277 1
Via Olgettina 58
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.